好奇學生大哉問連結台灣專題講座2023年 3月專題講座
主題：浴火重生-從大災難中學習如何生存 (Learning from Catastrophes)
主講： 蔡果荃教授
地點：遠距視訊 (WebEx Video Conference)
Webex 的進場信息，在您登記後，系統會自動告知登錄成功，並將聯絡網址告知。
時程：3/17/2023 （星期五）10:10 - 11:45 noon (台北時間)
3/16/2023 (Thursday) 7:10 - 8:45 PM (Los Angeles time)
|
時間(TPE) |
內容 |
講者/主持人 |
|
09:00~9:30 |
網路設備測試 |
場控 |
|
09:30~10:10 |
進場 |
演講前導影片 |
|
10:10~10:15 |
開幕致詞 |
主持人 |
|
10:15~10:18 |
介紹主講者 |
大同校長 何明果 |
|
10:18 –10:50 |
演講 |
蔡果荃教授 |
|
10:50~11:40 |
問題與討論 |
蔡果荃教授 及主持人 |
|
11:40~11:45 |
謝幕 |
主持人 |
講者簡介：
嘉賓： 蔡果荃 教授
職銜：
- 加州大學洛杉磯分校醫學院精神病學與生物行為科學系教授
- 美國國家發明家學院院士
- 心悅生醫(SyneuRx) 執行長
“Extinction is the rule. Survival is the exception.” Over 99% of all species that ever lived are now extinct. However, no species ever became extinct that did not first survive. The true exception is not survival, but continued survival, something that requires a species to show ongoing learning while enjoying continual and timely good luck. The most critical to survival is learning. Both learning from history and learning from here and now are critical. In fact, learning from catastrophe, for examples, pandemic, nuclear war, climate change, would be most rewarding. This principle is not applied to human race alone, organism, institution, race and nation, all need to learn, to adapt, to create and to survive.
在本次演講您可學到下列知識：
- 從歷史中吸取教訓，學習如何生存
- 生存最關鍵的是學習
經歷：
蔡果荃教授在腦科學、精神病學和管理方面的專業知識始於台灣國立陽明大學、約翰霍普金斯醫學院和馬里蘭州巴爾的摩凱瑞商學院的教育。 他曾在麻省總醫院和麥克萊恩醫院接受培訓，這兩家醫院是哈佛醫學院世界一流的普通精神病學和兒童及青少年精神病學教學醫院，他是美國精神病學和神經病學委員會成人和兒童精神病學的外交官。 他當選為美國國家發明家學院院士和美國神經精神藥理學會院士，並且是神經科學學會的成員。 他發表了一百多篇科學論文，被引用了一萬五千次，並獲得了一百多項專利。 他的開創性研究開啟了谷氨酸能治療腦部疾病的領域； 他是第一個報告 NMDA 調節對多種中樞神經系統疾病的療效的人； 這為這一系列的新療法定下了基調。 他驗證的新治療類別包括：NMDA 受體的完全和部分激動劑、甘氨酸轉運蛋白抑製劑和 D-氨基酸氧化酶抑製劑。 這些發現是 SyneuRx（TT6575）製藥企業的基石，該公司成立於 2013 年，目前在 CNS 治療領域擁有世界領先的管線。 最近，他發現了一系列新化學物質，它們是用於處理 SARS-CoV-2 病毒蛋白的 3CL 蛋白酶抑製劑和用於 SARS-CoV-2 和流感病毒病毒進入的 TMPRSS2。 這些治療實體將推進 COVID-19 和流感的治療選擇。
Dr. Tsai was a faculty at Harvard Medical School and now professor at UCLA School of Medicine, Department of Psychiatry and Biobehavioral Sciences. His expertise in brain science, psychiatry and management started with education at National Yang-Ming University, Taiwan, Johns Hopkins Medical School and Carey School of Business, Baltimore, Maryland. Trained at Massachusetts General Hospital and McLean Hospital, world rank teaching hospitals of Harvard Medical School in general psychiatry and child and adolescent psychiatry, he is a diplomate of American Board of Psychiatry and Neurology on both adult and child psychiatry. He is elected to fellow of National Academy of Inventors, and American College of Neuropsychopharmacology and is a member of Society for Neuroscience. He has published more than one hundred scientific articles with fifteen thousand citations as well as more than one hundred patents. His pioneer research opens the field of glutamatergic treatment for brain disorders; he is the first to report the therapeutic efficacy of NMDA modulation for a wide variety of CNS disorders; that set the tone of this line of novel treatment. The new therapeutic classes he validates include: full and partial agonists of NMDA receptor, inhibitors for glycine transporter inhibitor and D-amino acid oxidase. These discoveries are the corner stone of the pharmaceutical venture of SyneuRx (TT6575), founded in 2013, which now has a world-leading pipeline in CNS therapeutics. Recently, he discovered an array of novel chemicals that are inhibitor of 3CL protease for processing of SARS-CoV-2 viral proteins and TMPRSS2 for viral entry of both SARS-CoV-2 and influenza viruses. These therapeutic entities will advance the therapeutic options for COVID-19 and influenza.
|
【獎勵金說明】 歡迎你們正式進入好奇學生大哉問的殿堂！我們在各演講前辦了一個「獎勵金」， 提供受獎同學每人最高 2,800 元。歡迎大哉問的新血一起來提問。 本活動獎勵金之相關規定如下: 【第一階段提問期限】 至3月16日21:00 (TPE) |
